Dianne Madelyn Finkelstein, Ph.D.
Co-Author
This page shows the publications co-authored by Dianne Finkelstein and Paul Goss.
Connection Strength
3.114
-
A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS137.
Score: 0.481
-
Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011. Breast. 2017 Feb; 31:197-201.
Score: 0.176
-
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 2016 Mar; 56:85-92.
Score: 0.167
-
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015 Apr 16; 17:56.
Score: 0.158
-
Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis. Breast Cancer Res Treat. 2015 Jan; 149(1):255-61.
Score: 0.154
-
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy. Br J Cancer. 2014 Nov 25; 111(11):2046-50.
Score: 0.152
-
Access to care issues adversely affect breast cancer patients in Mexico: oncologists' perspective. BMC Cancer. 2014 Sep 09; 14:658.
Score: 0.151
-
Breast cancer in China. Lancet Oncol. 2014 Jun; 15(7):e279-89.
Score: 0.148
-
Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol. 2014 Aug 01; 32(22):2296-303.
Score: 0.147
-
Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study. Cancer Epidemiol Biomarkers Prev. 2014 Jan; 23(1):126-33.
Score: 0.143
-
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst. 2013 Jul 17; 105(14):1036-42.
Score: 0.139
-
Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013 Apr; 14(5):391-436.
Score: 0.137
-
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Jan; 14(1):88-96.
Score: 0.134
-
Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol. 2012 Aug; 13(8):e335-43.
Score: 0.131
-
Breast cancer in Brazil: present status and future goals. Lancet Oncol. 2012 Mar; 13(3):e95-e102.
Score: 0.127
-
Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort. J Clin Oncol. 2011 Sep 20; 29(27_suppl):2.
Score: 0.123
-
A phase II clinical trial of drug withdrawal in women with progressive breast cancer while on aromatase inhibitor therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):559.
Score: 0.120
-
A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS152.
Score: 0.120
-
Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Front Oncol. 2018; 8:156.
Score: 0.049
-
Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. Cancer Discov. 2018 03; 8(3):336-353.
Score: 0.047
-
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015 Jun 10; 33(17):1902-9.
Score: 0.039
-
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer. 2015 Apr; 51(6):685-96.
Score: 0.039
-
TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol. 2011 May 20; 29(15_suppl):1025.
Score: 0.030
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.